How MIT Became MIT: A Deep Dive into Its Technology Licensing Office

The Massachusetts Institute of Technology (MIT) is one of the premier institutions for fostering entrepreneurship, leading global frontier technological innovations and their extensive market applications. However, what sets MIT apart from other universities is not only the exceptional intellect of its students and faculty but also the soul of its innovation: the Technology Licensing Office (TLO). This dynamic engine of creativity propels disruptive ideas from the laboratory to the marketplace, igniting a revolution that transforms human destiny.

Supported by the Bayh-Dole Act of 1980, MIT rapidly established its Technology Licensing Office (TLO) to perfect a self-sustaining cycle that transforms cutting-edge basic research into commercially viable technologies. This initiative enables university scientific achievements to be effectively applied in the market, generating revenue that feeds back into both the university and society at large. This article attempts to explore the subtle synergy between MIT and the TLO, uncovering the secrets behind their steadfast commitment to turning dreams into reality, and explaining why this partnership has propelled MIT to the forefront of global progress in the 21st century.

According to recently released data, MIT received a total of 696 invention disclosures in fiscal year 2022, filed 311 new U.S. patent applications, and had 354 new patents granted. It licensed out 145 patents, incubated 27 spin-off companies, and generated $82.7 million in licensing revenue.

In summary, MIT professors submitted nearly 700 inventions they deemed worthy of development during the year. The Technology Licensing Office (TLO) determined that approximately 45% of these warranted further resource investment and filed patent applications accordingly. Following the USPTO’s timeline, 354 applications accumulated over the past three or more years are expected to be approved this year, with a 40% grant rate. This process has led to the incubation of startups and generated licensing revenue.

"354 domestic patents approved in one year—this would likely get a university stripped of its 'Double First-Class' status in China."

Jokes aside, we are not going to engage in hollow praise by claiming that MIT has a small number of high-quality patents, as there are practical issues involved that we will elaborate on later. Instead, here lies a seemingly inconspicuous piece of data that is actually the most valuable.

474 International Patents Granted

What does this figure signify? The underlying message is that every U.S. domestic patent granted to MIT is highly competitive. These inventions, having secured U.S. domestic patents, are also recognized by the Technology Licensing Office as possessing strong global competitiveness, necessitating the protection of their interests on a worldwide scale.

A review of the relevant data on MIT patent licensing over the past five years also largely aligns with this trend.

On average, 780 invention disclosures are submitted annually to the Patent Licensing Office, with nearly 50% proceeding to patent application filings, and the vast majority of these applications being granted. Approximately 40% of the granted patents are licensed externally, either to startups or to external enterprises. The annual volume of granted international patents is comparable to that of granted domestic patents.

The MIT Technology Licensing Office has a total of 54 employees. These 54 staff members include 6 in management, 4 licensing specialists in life sciences, 4 licensing specialists in physics and software, 9 execution specialists who assist the aforementioned eight specialists in their daily work, 6 finance personnel, 5 patent administrative specialists, 2 marketing personnel, 8 IT staff, 3 administrative staff, and 6 interns. According to the 2021 Annual Report on the Transformation of Scientific and Technological Achievements in China, half of Chinese universities and research institutions have an average of 7.7 full-time employees engaged in technology transfer-related work, while the other half have none.

Let’s take a closer look at the backgrounds of these MIT employees.

Lesley Millar-Nicholson

Director Lesley Millar-Nicholson earned her MBA from the University of Illinois at Urbana-Champaign (UIUC), an institution renowned for its vibrant entrepreneurial and innovative atmosphere. After graduating in 2002, she joined the UIUC Office of Patent Management and Licensing, where she served for 14 years, including 10 years as Director. It was during this period that AbbVie, a prominent biopharmaceutical company, spun off from Abbott Laboratories. In 2016, she joined the MIT Technology Licensing Office (around the time when Tsinghua University’s Office of Achievements and Intellectual Property Management was newly established) and was promoted to Executive Director.

Lauren Foster

Deputy Director Lauren Foster holds a B.S. in Molecular Biology and a Ph.D. in Molecular Biology from Harvard University, and served at the MIT Technology Licensing Office for 17 years.

Jonathan Hromi

Deputy Director Jonathan Hromi holds a B.A. in Biology from Johns Hopkins University and a J.D. from Case Western Reserve University School of Law. He is admitted to the bar in both Rhode Island and Massachusetts and is a seasoned attorney who previously founded his own law firm.

4 Licensing Specialists in the Life Sciences SectorHolding PhDs from Cornell University and Harvard University, respectively, along with a former clinician and a former pharmaceutical executive, all four individuals have extensive work experience in life sciences companies.

4 Licensing Specialists in Physics and SoftwareThey include a Ph.D. in Chemistry from the University of California, Los Angeles; a J.D. in Electrical Engineering from Rutgers University; a former R&D Director with a Ph.D. in Chemical Engineering; and a former Bose engineer who is a U.S. Navy veteran.

Other staff members hold advanced degrees and possess years of experience in their respective fields. Among the seven interns, several are currently pursuing JD or PhD degrees.

All work conducted by the MIT Patent Licensing Office can be categorized into these three areas:Assessment, Protection, Empowerment。

Assessment:

With billions of dollars in annual research funding from U.S. taxpayers, the research achievements created by MIT researchers using university laboratory facilities during their tenure are, simply put, owned by the university. This is, of course, a well-worn topic. Furthermore, before MIT researchers publicly disclose any breakthrough in their research findings in the form of reports or articles, they must promptly submit an Invention Disclosure to the Technology Licensing Office.

Why? To safeguard the interests of universities and researchers. For instance, if an invention disclosure is not filed in a timely manner and the findings are publicly disclosed, such information enters the public domain. After a specified period, third parties who were not involved in the related research may file patent applications for these inventions. Universities and researchers would then be unable to take action and would suffer certain economic losses. The university’s research funding would be wasted, and researchers would miss out on commercialization opportunities.

The evaluation system is not complex; it primarily assesses whether the submitted invention has market potential. Internal documents reveal that the questions in the first round were surprisingly straightforward:

• What problems can this technology solve?

• Is it a disruptive technology or an incremental improvement?

• Has a proof of concept been conducted?

• How does it differ from the current approaches to addressing the issue?

• Are companies in the industry investing in and/or commissioning the development of related technologies?

• Is the market size large enough to absorb the cost of the technology?

  
  

The subsequent evaluation of patent applications and their grantability is also straightforward:

• Does the technology possess uniqueness, novelty, and non-obviousness (unique to U.S. patent applications)?

• Can the patent application secure a sufficient number of claims (i.e., how broad can the scope of protection be)?

• Is applying for a patent the best way to enable reasonable access to technology usage rights across the entire market (and how large a market can it benefit)?

• Does the technological R&D involve multiple institutions (how many parties are sharing the pie)?

  
  

Don’t these questions feel remarkably similar to those that investment firms would ask, or expect you to address in your business plan (BP) upfront?

Inventive disclosures submitted at this stage that lack sufficient market potential will be rejected, with the option to resubmit after further refinement of experimental data. Inventions with adequate market potential will advance to the next stage of the pipeline. Even with a team of over 50 employees, the department can only process 300–400 applications annually. Achievements lacking commercialization potential must be rejected; streamlining is essential.

Protection:

At this stage, the Patent Licensing Office collaborates with external patent law firms, building upon the work of internal legal counsel, to file patent applications. The primary reason for this approach is that patent applications have extremely stringent requirements for material submission; the drafting of claims directly determines whether the patent can take effect and safeguard rights during critical periods (interested readers may search for the case of Gu Tailai v. Yonganxing). Furthermore, as these inventions involve multiple disciplines, a thorough understanding of both technology and market dynamics is essential to ensuring the quality of the application materials.

The patent application process in the United States is lengthy, typically taking at least three years and requiring repeated submissions of supplementary materials and responses to office actions. Researchers with urgent needs for technology development and publication can obtain a 12-month provisional protection, as detailed in the previous article “From 0 to 99: A University Professor’s Entrepreneurial Journey.” This provisional protection will convert into a formal patent upon approval.

It is evident that applying for patents in the United States imposes high demands in terms of professional expertise, financial investment, and time commitment. This explains why MIT files only slightly more than 300 patent applications per year, as mentioned at the beginning. The reason is cost: although the expenses are covered by university funds and commissions from licensing revenues allocated to the Technology Licensing Office, they still count against the department’s own budget. Moreover, since most of these technologies have the potential for global commercialization, the costs associated with filing and maintaining international patent protections are exceedingly high.

In China, ultra-low patent agency fees have long been a unique phenomenon, driven by varying university assessment criteria and a vicious cycle of low-price bidding among university-appointed patent agencies. The average winning bid for university invention patent agency services can be as low as RMB 3,000, only a few hundred yuan higher than the official government fees. I would not even hire someone to write an elementary school essay for a few hundred yuan, let alone entrust them with drafting patent claims that safeguard my invention rights for up to 20 years. In recent years, state-owned law firms have entered the market, charging higher fees and deploying more qualified professionals to improve the quality of patent drafting, including in fields such as new energy batteries, with the hope of exerting a positive influence on the industry.

Authorization:

Once an invention progresses from research findings to a stage eligible for patent granting, its subsequent trajectory becomes relatively fixed. Here, we will not address the risks associated with technological commercialization; instead, we will focus solely on the flow of assets.

As institutional assets, approved patents are licensed to companies for commercialization. Over 60% of exclusive licenses are granted to university spin-off startups, with the aim of maximizing returns. More than 80% of non-exclusive licenses are awarded to external enterprises, in an effort to control risks and costs.

As corporate assets, revenues generated from granted patents (and even future equity stakes) are distributed back to the university, inventors, academic departments, laboratories, and the Technology Licensing Office according to pre-negotiated ratios. Fifteen percent of the total annual licensing revenue is allocated to the Technology Licensing Office as administrative funding. Yes, this refers to 15% of the $80 million mentioned at the beginning.

It is worth noting the Patent Licensing Office’s high level of engagement. The office wields substantial influence over a range of provisions designed to safeguard the university’s revenue, including licensing fees, sales royalties, sublicense income, and equity dilution clauses. As the university’s representative and a beneficiary of revenue sharing, the Patent Licensing Office demonstrates strong objective and subjective initiative.

The level of scientific research capability is a macro-level issue encompassing numerous facets, warranting more time for understanding and analysis. However, from a micro-level perspective, the practical operation and execution of specific tasks can be rapidly improved through institutional adjustments. It is worthwhile to pilot in China whether the rational redesign of performance metrics and discretionary budgets can stimulate greater individual initiative and optimize workflow processes.

As for the insights we can draw, let us conclude this serious discussion on a light note with a few lines of rough doggerel.

With the documents in hand, I know who to contact.

Traceable processes, accountable personnel

Don’t be disheartened if your application is rejected.

After all, the division has to advance the legal fees.

The preparation of materials must absolutely not be diluted.

You’ll have no recourse if your rights are infringed later.

Collective Deliberation on Income Distribution

Trust Is Backed by Explicit Regulations

If the company goes under, you won’t be held responsible.

The company’s profits wouldn’t be possible without your share.